B cell lymphoma prognosis

Diffuse Large B Cell Lymphoma: Five Factors For A Prognosi

  1. ed by using a well-established and reliably predictive model known as the Revised International Non-Hodgkin's Lymphoma Prognostic Index (IPI or R-IPI)
  2. Diffuse large B-cell lymphoma (DLBCL) tends to grow quickly. Most often, the treatment is chemotherapy (chemo), usually with a regimen of 4 drugs known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), plus the monoclonal antibody rituximab (Rituxan). This regimen, known as R-CHOP, is most often given in cycles 3 weeks apart
  3. e progression-free.
  4. Diffuse large B-cell lymphoma is a non-Hodgkin's lymphoma (NHL). Out of over 60 types of NHLs, diffuse large B-cell lymphoma is the most common. DLBCL is the most aggressive or fast-growing form of..

Treating B-Cell Non-Hodgkin Lymphom

Diffuse large B-cell lymphoma (DLBCL) This is the most common type of NHL in the United States, accounting for about 1 out of every 3 lymphomas. The lymphoma cells look fairly large when seen with a microscope. DLBCL can affect people of any age, but it occurs mostly in older people If your doctor tells you that you have B-cell lymphoma, it means you have a cancer that forms in white blood cells called lymphocytes. There's a lot to take in at first, but your doctor can explain.. These so-called b- lymphoma symptoms are things like night sweats, fever and weight loss, and indicate the cancer is more serious than it would be in a person at the same stage but without noticeable signs Outlook The overall five-year relative survival rate for non-Hodgkin's lymphoma is 70 percent. This varies a lot according to the type of B-cell lymphoma and stage at diagnosis. Other..

T-Cell Lymphoma Prognosis. In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of the reasons this is the case is because T-cell lymphomas are much rarer than B-cell lymphomas, representing about 15% of all lymphoma diagnoses in the United States annually Also if they have a T-Cell Lymphoma, chances are that dogs will go into remission, but they will relapse much quicker, perhaps as quickly as within 4 months from the start of treatment, compared to dogs with B-Cell Lymphoma, whose first remission can often last as long as 12 to 18 months or longer

High-Grade B-Cell Lymphomas, Not Otherwise Specified: A

But it's important to keep in mind that survival rates can vary widely for different types and stages of lymphoma. Below are the 5-year relative survival rates for two common types of NHL - diffuse large B-cell lymphoma and follicular lymphoma - based on people diagnosed between 2010 and 2016. Diffuse large B-cell lymphoma B lymphocytes are supposed to grow into cells that help you fight infections. But in this disease, they turn into leukemia cells that live longerthan normal cells and reproduce quickly. They..

Diffuse Large B-Cell Lymphoma: Prognosis, Symptoms, and Cause

Blink-182's Mark Hoppus revealed that he is fighting diffuse large B-cell lymphoma (DLBCL), an aggressive type of non-Hodgkin lymphoma. Here's what you should know about the aggressive type of cancer The 49-year-old rocker shared that he has diffuse giant B-cell lymphoma Stage 4-A throughout a Twitch dwell stream with followers, which was captured and reuploaded by a Blink 182 fan account on YouTube. Hoppus was very open along with his followers all through the dwell stream, sharing detailed specifics about his prognosis and therapy Intravascular large B-cell lymphoma is a rare malignancy characterized by the presence of lymphoma cells within the lumen of blood vessels. The annual incidence of cases is fewer than 0.5 cases per 1,000,000. It usually affects the elderly with an average age of diagnosis around 70 years. Due to the absence of lymphoma cells in the peripheral smear and lymphadenopathy, it is difficult to. Primary cutaneous diffuse large B-cell lymphoma, leg type is a distinct entity with a poor prognosis, particularly in patients with multiple tumors on the legs. Despite the advanced age of many patients, the prognosis could be improved with combinations of anthracycline-containing chemotherapies and

The 49-year-old singer revealed particulars of his prognosis on a Twitch stream, saying he has diffuse massive B-cell lymphoma Stage 4-A. My classification is diffuse massive B-cell lymphoma Stage 4-A, which implies, as I perceive it, it's entered 4 completely different components of my physique, the singer defined Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies.It is the most common form of non-Hodgkin lymphoma among adults, with an annual incidence of 7-8 cases per 100,000 people per year in the US and UK. This cancer occurs primarily in older individuals, with a median age of diagnosis at ~70 years, although it can occur. Because of the heterogeneity among older patients with diffuse large B‐cell lymphoma (DLBCL), the establishment of an easy‐to‐use geriatric assessment tool is an unmet need. We verified the impact of the Geriatric 8 (G8) on treatment stratification and overall survival (OS). We conducted a retrospective, multicentre analysis of older patients (≥65 years) with DLBCL Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is potentially curable. DLBCL is the most common non-Hodgkin lymphoma (NHL) representing about 25-35% of all new cases of NHL. Precursor B-cell lymphoblastic lymphoma (B-LBL) is uncommon and accounts for less than 10% of cases of lymphoblastic lymphoma. We collected 25 cases of B-LBL, occurring in children and adults, and report the clinical and histologic features. Patients with concurrent precursor B-cell acute lymphoblas

Types of B-cell Lymphom

Background: B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL) show many overlapping morphologic and immunophenotyping features, however they have great difference in therapeutic regimens and prognosis. The aim of the study: Is to determine the diagnostic and prognostic role of clinico-pathologic variables, CD23 and Cyclin D1 oncoprotiens. Prognosis for Mantle Cell Lymphoma. Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma and is one of the rarest forms of Non-Hodgkin's lymphoma, accounting for six percent of non-Hodgkin's cases, for a total of around 15,000 patients in the US. It is one the more difficult to treat lymphomas, although, while not often cured, the. The long-term survival rate for children with advanced (stage III or IV) diffuse large B-cell lymphoma ranges from about 80% to 90%. For advanced anaplastic large cell lymphoma, the long-term survival rate is about 60% to 75%. Remember, all of these survival rates are only estimates - they can't predict what will happen with any child

What Is B-Cell Lymphoma? - WebM

  1. The Revised International Prognostic Index (R-IPI) for Diffuse Large B-cell Lymphoma predicts overall and progression free survival based on risk factors. This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis
  2. Diffuse large B-cell lymphoma (DLBCL) is the most frequently observed hematologic malignancy with 45,000 patients newly diagnosed globally each year. DLBCL patients can be cured if successfully treated with first line therapy, but patients who relapse face a poor prognosis
  3. Diffuse large B-cell lymphoma (DLBCL) represents 30% of non-Hodgkin's lymphoma. Long-term disease-free survival is now a reality for at least 50% of patients and can reach more than 80% when lymphoma is localized at diagnosis. 1,2 Unfortunately, some patients eventually relapse, mainly in the first 2 to 3 years following treatment. Late relapses that occur after 5 years have been described but.
  4. Prognosis of primary mediastinal large B-cell lymphoma The long-term, event-free survival rate for childhood primary mediastinal large B-cell lymphoma is about 70 percent. There is a need for improved treatment approaches which may include novel targeted therapy
  5. Introduction. For several decades, CHOP [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PSL)] therapy combined with rituximab (R-) has been considered the standard regimen for diffuse large B-cell lymphoma (DLBCL). 1 Conventionally, six cycles of R-CHOP-21 have frequently been used in clinical practice, but data supporting the optimal number of treatment cycles.
  6. Primary cutaneous B-cell lymphomas (CBCLs) occur when the lymphoma cells originate in B lymphocytes. CBCLs are most often indolent (slow-growing). They may appear on the skin as a reddish rash, lump, or nodule and may have a slightly raised and smooth appearance. The disease tends to recur (return after treatment) in new places on the skin, but.

The main types of B-cell non-Hodgkin lymphoma (NHL) are listed here, along with estimates for the number of new cases annually expected in the United States: Diffuse large B-cell lymphoma (DLBCL): More than 18,000 new cases. Follicular lymphoma (FL): 15,000 new cases. Marginal zone lymphomas (MZL): 6,000 new cases About Lymphoma > Metastasis of Lymphoma?. It's a misnomer . Last update: 03/07/2014 TOPIC SEARCH: PubMed Metastasis is the spread of cancer from its primary site to other places in the body Cancer cells can break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream, and grow in a distant focus (metastasize) in normal tissues elsewhere in. Without treatment, a typical prognosis for a patient with brain lymphoma is life expectancy of less than two months, according to the New York Times Health Guide. With chemotherapy treatment, patients typically live three to four years or longer, depending on the return or continued remission of the tumor Primary Mediastinal Large B-Cell Lymphoma is a subtype of diffuse large B-cell lymphoma. The cure rate of PMBCL is similar to the cure rate of DLBCL and the 5 year survival rate is 50% In general, the prognosis depends upon a set of several factors, which include

Learn about lymphoma. If you'd like to know more about your lymphoma, ask your doctor for the details of your cancer — the type, the stage and your prognosis. Ask for good sources of up-to-date information on your treatment options. Knowing more about your cancer and your options may help you feel more confident when making treatment decisions Prognosis. Treatment. Lymphoblastic lymphoma is an uncommon form of fast-growing, aggressive non-Hodgkin lymphoma (NHL), most often seen in teenagers and young adults. Another name for it is precursor lymphoblastic lymphoma. It usually is a tumor of the T cells but sometimes the cells are B cells, and those terms will be used in naming. 1  CAR-T cell therapy might be an option for certain types of B-cell non-Hodgkin's lymphoma that haven't responded to other treatments. Bone marrow transplant. Bone marrow transplant, also known as a stem cell transplant, involves using high doses of chemotherapy and radiation to suppress your bone marrow and immune system. Then healthy bone. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year. DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes

Non-Hodgkin lymphoma, in contrast to Hodgkin lymphoma, can come from B-type or T-type immune cells. It can also form in the lymph nodes and other organs, such as the stomach, intestines, and skin Primary cutaneous large B cell lymphoma, leg type View in Chinese Primary mediastinal large B cell lymphoma View in Chinese Prognosis of diffuse large B cell lymphoma View in Chinese Relapsed or refractory diffuse large B cell lymphoma View in Chinese Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma View in Chines High grade (aggressive) non-Hodgkin lymphoma is a fast-growing disease. Yet it responds well to treatment and many patients can be cured. The outcome depends on five well-established prognostic factors that make up the International Prognostic Index (IPI). Here is a description of these prognostic factors and how they affect outcomes Follicular lymphoma is known as an elderly lymphoma because your risk increases when you exceed age 75. In some cases, follicular lymphoma can progress to become diffuse large B-cell lymphoma. Characterization of tumors at the molecular level has improved our knowledge of cancer causation and progression. Proteomic analysis of their signaling pathways promises to enhance our understanding of cancer aberrations at the functional level, but this requires accurate and robust tools. Here, we develop a state of the art quantitative mass spectrometric pipeline to characterize formalin.

What Is the Prognosis for Lymphoma

B-cell lymphomas with a high content of T cells, occasionally misinterpreted as T-cell lymphomas in the past, have been recognized as a peculiarity by pathologists and were, therefore, indicated as T-cell-rich B-cell lymphoma.1 Initial studies demonstrated that a particular subgroup of T-cell-rich B-cell lymphomas mirror nodular. The most common subtype, diffuse large B-cell lymphoma, has a 40% lifetime relapse rate.37 Lifetime relapse in Hodgkin lymphoma occurs in 10% to 15% of patients with early stage disease and 40% of. Primary effusion-based lymphoma (EBL) presents as a malignant effusion in a body cavity. The clinicopathologic features and prognosis of primary human herpesvirus 8 (HHV8)-negative EBL remain unclear. We therefore conducted a retrospective study of 95 patients with EBL, regardless of HHV8 status, in

B-Cell Lymphoma: Outlook, Treatment, Types, and Mor

Diffuse large B-cell lymphoma symptoms, diagnosis and

In addition to primary CNS lymphoma, other types of systemic non-Hodgkin lymphoma can invade the brain and cause neurologic symptoms. Lymphomas are divided into the Hodgkin and non-Hodgkin types; the latter being divided in several subtypes such as diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma Canine Lymphoma is a broad term that describes any type of cancer that affects Lymphocytes. However, there are actually many different Canine Lymphoma Types, with the primary types generally classified by the area the body primarily affected.. Because Lymphocytes are found throughout the body, all types of Canine Lymphoma are considered to be systemic - that is, affecting the body as a. The lymphoma is called 'double hit' because unlike a vast majority of lymphomas that have a single genetic mutation, the Double Hit Lymphoma has 2 mutations. In general, there are many subtypes of lymphomas such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), etc Lymphoma is a cancer of the lymph nodes and lymphatic system. This cancer may be localized to one particular region, or may spread throughout the entire body. Lymphoma is a relatively common cancer, accounting for 15-20% of new cancer diagnoses in dogs. The prognosis for lymphoma varies, depending on various characteristics that can only be determined by specialized testing Diffuse large B cell lymphoma (DLBCL) is a cancer of B lymphocytes. Almost all lymphocytes begin growing in the bone marrow or lymph nodes. T cells leave the bone marrow before they are completely matured, and finish maturing in the thymus gland. B cells instead continue to develop and mature in the bone marrow and lymph nodes

Primary cutaneous marginal zone B-cell lymphoma (CMZL) is the second most common form of CBCL. CMZL is a low-grade B-cell lymphoma that is similar to the MALT (mucosa-associated lymphoid tissue) type lymphomas.. This slow-growing B-cell lymphoma appears as pink or red papules, nodules and/or tumors. Although CMZL can occur anywhere on the body. Several studies have reported improved clinical outcomes in patients with FL3 treated with rituximab (R), approved in early 2006, as a first line therapy for diffuse large B-cell lymphoma. The aim of this population based study is to compare the overall survival and disease specific survival in patients diagnosed with FL3 prior to and after 2006 The prognosis of Non-Hodgkin's lymphoma depends upon the stage at which the disease is diagnosed, age of the patient, organs involved and the response of patient towards treatment. As the stage progresses, more aggressive treatment is required with low cure rate. The overall survival rate of stage 4 lymphoma is 55-60% Canine Lymphoma Prognosis. Perhaps the most important question dog owners want answered about canine lymphoma is the survival rate. We want to know how long a dog diagnosed with lymphoma has to. Primary mediastinal large B-cell lymphoma is a rare lymphoma subtype associated with bulky mediastinal mass and usually presents in young females. Its prognosis

T-Cell Lymphoma Prognosi

The term cutaneous T-cell lymphoma describes a group of typically indolent lymphomas that appear on, and are most often confined to, the skin. Mycosis fungoides, which appears as skin patches, plaques, or tumors, is the most common type of CTCL. Patches are usually flat, possibly scaly, and look like a rash; plaques are thicker, raised, usually. With combination chemotherapy, the expected survival time for dogs with B-cell lymphoma is ~12 months, whereas for dogs with T-cell lymphoma, expected survival times are often in the range of 6 months. Although immunophenotype (B- versus T-cell) provides a general guideline for treatment prognosis, multiple factors (tumor and host) contribute. Diffuse large B-cell lymphoma (DLBCL) affects both men and women (although slightly higher in men) and over half the cases are aged in people over 60 years. However, DLBC can also be diagnosed in children, adolescents and young adults. Treatments can also be different depending on the age of the person being treated

Canine Lymphoma Life Expectancy - CanineLymphoma

Hodgkin's lymphoma (formerly called Hodgkin's disease) Non-Hodgkin's lymphoma; What lymphoma treatment is best for you depends on your lymphoma type and its severity. Lymphoma treatment may involve chemotherapy, immunotherapy medications, radiation therapy, a bone marrow transplant or some combination of these Primary hepatic lymphoma (PHL) is a rare disease that accounts for only 0.1% of liver malignancies, 0.4% of extranodal lymphomas, and 0.016% of non-Hodgkin's lymphomas (NHL). 1,2 Primary hepatic marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma accounts for only 3% of all cases of PHL. 3 The concept of MALT lymphoma was first proposed by Isaacson and Wright in 1983 to. B-cell lymphoma is associated with longer survival and better quality of life. 1,2. CHEMOTHERAPY Treatment Goals. The goal of lymphoma treatment is to induce clinical remission, indicated by lack of measurable disease, while retaining a high quality of life. Because lymphoma is a systemic disease, chemotherapy is the foundation of treatment MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies.The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic. Marginal Zone Lymphoma. Marginal zone lymphoma (MZL) is a group of indolent (slow growing) NHL B-cell lymphomas, which account for approximately eight percent of all NHL cases. The average age at diagnosis is 60 years, and it is slightly more common in women than in men

Primary cutaneous diffuse large B-cell lymphoma, leg type manifests as rapidly progressive red-brown to blue tumors in either 1 or both legs, which may be ulcerated or surrounded by smaller, satellite lesions. This type of lymphoma is most frequently reported in older women, and approximately 10% to 15% of cases may also include other cutaneous. Burkitt lymphomas are aggressive B-cell cancers that require urgent diagnosis and therapy.; The cause of these lymphomas is not known, but does involve a change in chromosome 8 and may be related to infections such as malaria and/or Epstein-Barr virus infections.; There are many signs and symptoms associated with Burkitt's lymphoma; most commonly, the symptoms include abdominal and/or jaw. A small number of people with chronic lymphocytic leukemia may develop a more aggressive form of cancer called diffuse large B-cell lymphoma. Doctors sometimes refer to this as Richter's syndrome. Increased risk of other cancers The 5-year OS rate was 33% in MYC + DLBCL patients and 72% in patients with DLBCL without a MYC rearrangement (MYC-DLBCL).38 MYC + DLBCL with an additional rearrangement of BCL2 (or, alternatively, BCL6) had a worse prognosis.39, 40 B-cell lymphoma with multiple chromosome breakpoints (MYC, BCL2, BCL6) is described as double-hit lymphoma.

B-Cell lymphoma is caused by an issue with specialized white blood cells known as b-cells. Since most types of b-cell lymphoma develop very quickly, symptoms tend to emerge within a few weeks or months. In many cases, the first sign is swelling in one or more lymph nodes in the neck, groin, or armpits Double-Hit Lymphoma. Double-hit lymphoma (DHL) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) characterized by rearrangements (parts of genes switch places within chromosomes) in two particular genes. One rearrangement involves the MYC gene, and the other involves the BCL2 gene or, less commonly, the BCL6 gene

Cutaneous B-Cell Lymphoma. When extranodal lymphomas originate in the skin (comprising 18 percent of all extranodal lymphomas and five percent of all NHLs) and there is no evidence of disease outside of the skin, they are called primary cutaneous lymphomas CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell. The IPI24 provides an individual level 0-100% probability of achieving EFS24 for each patient and can be used for patient prognosis, treatment stratification, and risk assessment. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy When non-Hodgkin lymphoma comes back after treatment is completed, it is called a recurrence. Many types of non-Hodgkin lymphoma respond favorably to treatment, but it's still important for people who have achieved partial or total remission to be aware of the potential for a recurrence

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), and it accounts for approximately 25% of NHL cases. 1 The incidence of DLBCL in the United States is approximately 7 cases per 100,000 person-years, with a male predominance. 2 Caucasian Americans have higher rates than African Americans, Asians, and. Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25 percent of NHL cases [ 1,2 ]. (See Classification of the hematopoietic neoplasms .) The diagnostic category of DLBCL is morphologically, genetically, and biologically heterogeneous When lymphoma starts in the thymus or lymph nodes in the chest, it may press on the nearby trachea (windpipe), which can cause coughing, trouble breathing, or a feeling of chest pain or pressure. The superior vena cava (SVC) is the large vein that carries blood from the head and arms back to the heart

Adult non-Hodgkin's lymphoma (NHL) is a malignant cancer that begins in the lymph system. The lymph system is part of the body's immune system. Malignant means a disease spreads from where it starts and invades other areas of the body. Adult non-Hodgkin's lymphoma differs from lymphoma in children and has a different course of. Extranodal marginal zone B-cell lymphoma or mucosa-associated lymphoid tissue (MALT) MALT is the most common form of MZL. It can develop in the stomach (gastric) or outside the stomach (non-gastric) Gastrointestinal lymphoma is usually non-Hodgkin with the most frequent sites of occurrence in the stomach, small intestine and ileocecal region. Usually intestinal lymphoma is secondary, which means it was spread from a lymphoma that originated somewhere else. Diffuse large B-cell lymphoma is the most usual type of intestinal lymphoma Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is potentially curable. DLBCL is the most common non-Hodgkin lymphoma (NHL) representing about 30% of all cases of NHL in the.

The 2012 Oncology Nurse Hematology ConferenceFigure 5: Relapse of cutaneousRegression of Splenic Lymphoma with Villous Lymphocytes

Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma. The revised International Prognostic Index (R-IPI) was developed to predict the outcome of individuals receiving rituximab with chemotherapy. The score is able to differentiate patients into three groups (very good, good, poor. Primary vitreoretinal lymphoma (PVRL) is a variant of primary central nervous system lymphoma (PCNSL), which is generally an aggressive, diffuse large B-cell malignancy associated with poor prognosis. 1 The age-adjusted incidence of PCNSL in the Unites States is approximately 4.8 per million population, however, the exact incidence of PVRL is unknown. 2 The association between PVRL and PCNSL. Small lymphocytic lymphoma (SLL) is the third most commonly diagnosed subtype, after diffuse large B-cell and follicular lymphomas. It accounts for 5 to 6% of NHL cases or approximately 400 cases per year in the United States. Although some NHLs are very aggressive in nature, SLL is considered an indolent lymphoma Medical professionals are able to distinguish non-Hodgkin's from Hodgkin's lymphoma (formerly referred to as Hodgkin's disease) by examining the white blood cells affected by the disease. If the doctor does not detect what is known as a Reed-Sternberg cell, the lymphoma is classified as non-Hodgkin's. If there are Reed-Sternberg cells. The cancer is a form of extranodal, high-grade non-Hodgkin B-cell lymphoma. Most forms of CNS lymphoma (about 90 percent) are diffuse large B-cell lymphomas; the remaining ten percent are poorly characterized low-grade lymphomas, Burkitt lymphomas and T-cell lymphomas. Central nervous system lymphoma is more common in men than women A person with lymphoma and any one of the three symptoms above is said to have B symptoms. There are two major categories of lymphoma: Hodgkin lymphoma (HL) and non-Hodgkin Lymphoma (NHL). Patients with either type of lymphoma may develop B symptoms. One of the most common symptoms of lymphoma, in general, is the enlargement of lymph nodes